NCT07694115已完成1 期
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover Oral Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fasting Condition.
Humanis Saglık Anonim Sirketi1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年5月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Maximum concentration obtained (Cmax)
研究概览
简要总结
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets 25mg/1000mg in healthy subject in fasting condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants aged between 18 to 45 years (both inclusive).
- •Participants' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
- •Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
- •Participants having clinically acceptable 12-lead electrocardiogram (ECG).
- •Participants having clinically acceptable chest X-Ray (PA view), if taken.
- •Participants having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •Participants having negative urine alcohol test / breath alcohol test.
- •Non-smoker.
- •Participants willing to adhere to the protocol requirements and to provide written informed consent.
- •Participant with Creatinine Clearance ˃60 ml/min.
- •For male Participants: Participants willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Participants willing to refrain from donating sperm during the study period
- •For Female Participants: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam. Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
- •Participants having negative urine pregnancy test at screening and negative serum beta-hCG pregnancy test on admission day of period 01 (only for female participants).
排除标准
- •Hypersensitivity to Empagliflozin and Metformin or related class of drugs or any of its excipients or heparin.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- •Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period
- •Presence of alcoholism or drug abuse.
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer or basal or squamous cell carcinoma.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids dosage form like tablets or capsules.
- •Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period
- •Major illness within past 3 months.
- •Participant who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- •Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period
- •Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
- •Participants who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- •History of any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis).
- •History of Diabetic pre-coma.
- •History of acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.
- •History of disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.
- •History of Hepatic impairment or acute alcohol intoxication.
- •Female participants who are currently breast feeding.
结局指标
主要结局
Maximum concentration obtained (Cmax)
时间窗: 48 hours
two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data Cmax
AUC from time 0 to last collection time (AUC0 - t)
时间窗: 48 hours
two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC
次要结局
- Time to reach maximum concentration Cmax (Tmax)(48 hours)
- Area under the plasma concentration versus time curve from time 0 to 24 hour (AUC0-24)(48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsType 2 Diabetes Mellitus (T2DM)Cardiovascular DiseasesNCT07691203Humanis Saglık Anonim Sirketi36
已完成
2/3 期
A study to evaluate the blood levels of Brivaracetam SR Tablets 200 mg to measure the pharmacokinetic profiles, safety and tolerability of the Test product (of Optimus Pharma Pvt. Ltd.) when compared to the reference product (BRITZILAM SR Tablets 200 mg) in a healthy subject in a fasting condition.CTRI/2024/02/062873Optimus Pharma Pvt Ltd24
尚未招募
不适用
A study comparing how well the body absorbs two different formulations of Curcuma longa (Turmeric) extract in healthy adults under (fasting conditions).CTRI/2025/04/084854Chemiloids Life Sciences Private Limited.16
尚未招募
不适用
A bioequivalence study of Prazosin Hydrochloride tablets 5 mg in healthy human adult subjects under fasting conditionsCTRI/2025/04/083888Pfizer Limited,28
已完成
不适用
To study the bioequivalence of Relugolix 120 mg tabletsCTRI/2024/07/070478BDR Pharmaceuticals Internationals Pvt Ltd48